search
Back to results

Non-invasive Neuromodulation NESA Application in the Rehabilitation of Stroke Sequelae

Primary Purpose

Stroke

Status
Recruiting
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Non-invasive Neuromodulation
Placebo Non-invasive Neuromodulation
Sponsored by
University of Las Palmas de Gran Canaria
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Stroke focused on measuring physical therapy modality, Electric Stimulation Therapy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: People who have suffered a stroke with an evolution between 6 months and 6 years. Optimal cognitive capacity and mentally competent to participate in the study and complete the required questionnaires. People able of standing upright, including those who need technical aids. Exclusion Criteria: Present some of the contraindications for a treatment with NESA XSIGNAL®: pacemakers, internal bleeding, not to apply electrodes on skin in bad condition, with ulcerations or wounds, acute febrile processes, acute thrombophlebitis and/or phobia to electricity. Not having signed the informed consent form. Presenting any additional injury or pathology during the study. Not having the optimal cognitive capacities for understanding and participating in the study.

Sites / Locations

  • Mariola Lledó AmatRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Non-invasive Neuromodulation

Placebo Non-invasive Neuromodulation

Arm Description

The non-invasive neuromodulation experimental group, are treated 20 sessions with the NXSignal non-invasive neuromodulation device (NESA)

The non-invasive neuromodulation placebo group, are treated 20 sessions with the NXSignal non-invasive neuromodulation device (NESA)

Outcomes

Primary Outcome Measures

Change in Pain assessed by VAS
The instrument will be used to measure the change of pain before and after the intervention will be the Visual Analogue Scale (VAS). Participants will be asked to mark the level of their pain on a 100 mm, no hatched VAS scale marked at one end as "no pain" and at the other as "worst pain imaginable".
Change in Sleep quality
The Pittsburgh Sleep Quality Index (PSQI) will be used. It consists of 19 self-administered questions and 5 questions assessed by the patient's partner or roommate (if available). Only the self-administered questions are included in the score. The higher the total score, the worse the sleep quality. Thus, a total score less than or equal to five on the Pittsburgh scale indicates that, in general, your sleep quality is optimal, while a total score greater than five suggests that you have sleep problems, of greater or lesser severity.
Changes in quality of life
The Stroke-specific quality of life scale ( ECVI-38) is a specific scale for stroke patients. This instrument includes 38 items divided into eight subgroups: physical status, communication, cognition, emotions, feelings, basic activities of daily living, common activities of daily living and socio-familial functioning. The format presents five response possibilities: 5 represents the worst situation and 1 represents the absence of the problem.
Changes in the level of autonomy
The Barthel index for the level of independence in performing activities of daily living. The purpose of this questionnaire is to assign a score to each patient based on his or her degree of dependence in performing a series of basic activities. The values assigned to each activity depend on the time taken to perform them and the need for aids to complete them. activity of daily living include: eating, transferring between chair and bed, personal grooming, toileting, bathing/showering, transferring, going up/down stairs, dressing/dressing, stool control and urine control. The activities are assessed by assigning a score between 0, 5, 10 and 15 points and the final result can vary between 0 (completely dependent) and 100 points (completely independent).
Changes in their ability to balance
The Berg balance scale will be used: A quantitative measure of functional balance status in the elderly that has proven to be a valid, reliable and sensitive tool in hemiplegic patients. The Berg scale includes 14 items (scored between 0-4) and total scores range from 0 (severe balance impairment) to 56 (optimal balance status).
Changes in muscle tone
The modified Ashworth scale for spasticity will be used. A scale used in the clinic to assess muscle spasticity, the modification adds a level that incorporates the angle at which resistance appears and monitors the speed of passive movement with a one-second count. This scale is easy to use and can assess all joints, has a high degree of reliability and reproducibility. The score is interpreted as follows: 0 No increase in tone 1 slight increase in tone giving a catch when slight increase in muscle tone, manifested by the limb was moved in flexion or extension. 1+ slight increase in muscle tone, manifested by a catch followed by minimal resistance throughout (ROM ) 2 more marked increase in tone but more marked increased in muscle tone through most limb easily flexed 3 considerable increase in tone, passive movement difficult 4 limb rigid in flexion or extension

Secondary Outcome Measures

Full Information

First Posted
April 21, 2023
Last Updated
May 2, 2023
Sponsor
University of Las Palmas de Gran Canaria
search

1. Study Identification

Unique Protocol Identification Number
NCT05853952
Brief Title
Non-invasive Neuromodulation NESA Application in the Rehabilitation of Stroke Sequelae
Official Title
Non-invasive Neuromodulation NESA Application in the Rehabilitation of Stroke Sequelae. A Pilot Study
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 24, 2023 (Actual)
Primary Completion Date
October 24, 2023 (Anticipated)
Study Completion Date
December 23, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Las Palmas de Gran Canaria

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
To evaluate whether NESA microcurrents can be used as an effective treatment for various sequelae present in stroke patients, specifically in the treatment of spasticity, balance, pain; and whether it affects quality of life, performance of activities of daily living and quality of sleep.
Detailed Description
Pilot study following a randomized controlled trial design, designed to study the feasibility of a study with a larger sample size. Intervention of 30 stroke participants with an evolution between 6 months and 4 years since the stroke, who are able to stand upright. These participants will be recruited voluntarily through a campaign in social networks and with the collaboration of local associations and institutions. Once the inclusion and exclusion criteria have been reviewed, they will be randomly assigned to an intervention group and a placebo group. A double-blind recruitment system will be followed in which the physiotherapist and patients will not know whether they are receiving real or simulated stimulation, for this purpose two NESA XSIGNAL® devices will be used in double-blind mode. Treatment of 20 sessions per patient, of 1 hour duration each, with the NESA X-Signal device.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Stroke
Keywords
physical therapy modality, Electric Stimulation Therapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Non-invasive Neuromodulation
Arm Type
Experimental
Arm Description
The non-invasive neuromodulation experimental group, are treated 20 sessions with the NXSignal non-invasive neuromodulation device (NESA)
Arm Title
Placebo Non-invasive Neuromodulation
Arm Type
Placebo Comparator
Arm Description
The non-invasive neuromodulation placebo group, are treated 20 sessions with the NXSignal non-invasive neuromodulation device (NESA)
Intervention Type
Device
Intervention Name(s)
Non-invasive Neuromodulation
Intervention Description
The electrodes will be placed with the help of gloves and adapted socks for 1 hour, each session, until 13 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 millivolt and intensity 0.5 μA
Intervention Type
Device
Intervention Name(s)
Placebo Non-invasive Neuromodulation
Intervention Description
The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
Primary Outcome Measure Information:
Title
Change in Pain assessed by VAS
Description
The instrument will be used to measure the change of pain before and after the intervention will be the Visual Analogue Scale (VAS). Participants will be asked to mark the level of their pain on a 100 mm, no hatched VAS scale marked at one end as "no pain" and at the other as "worst pain imaginable".
Time Frame
Up to 7 weeks
Title
Change in Sleep quality
Description
The Pittsburgh Sleep Quality Index (PSQI) will be used. It consists of 19 self-administered questions and 5 questions assessed by the patient's partner or roommate (if available). Only the self-administered questions are included in the score. The higher the total score, the worse the sleep quality. Thus, a total score less than or equal to five on the Pittsburgh scale indicates that, in general, your sleep quality is optimal, while a total score greater than five suggests that you have sleep problems, of greater or lesser severity.
Time Frame
Up to 7 weeks
Title
Changes in quality of life
Description
The Stroke-specific quality of life scale ( ECVI-38) is a specific scale for stroke patients. This instrument includes 38 items divided into eight subgroups: physical status, communication, cognition, emotions, feelings, basic activities of daily living, common activities of daily living and socio-familial functioning. The format presents five response possibilities: 5 represents the worst situation and 1 represents the absence of the problem.
Time Frame
Up to 7 weeks
Title
Changes in the level of autonomy
Description
The Barthel index for the level of independence in performing activities of daily living. The purpose of this questionnaire is to assign a score to each patient based on his or her degree of dependence in performing a series of basic activities. The values assigned to each activity depend on the time taken to perform them and the need for aids to complete them. activity of daily living include: eating, transferring between chair and bed, personal grooming, toileting, bathing/showering, transferring, going up/down stairs, dressing/dressing, stool control and urine control. The activities are assessed by assigning a score between 0, 5, 10 and 15 points and the final result can vary between 0 (completely dependent) and 100 points (completely independent).
Time Frame
Up to 7 weeks
Title
Changes in their ability to balance
Description
The Berg balance scale will be used: A quantitative measure of functional balance status in the elderly that has proven to be a valid, reliable and sensitive tool in hemiplegic patients. The Berg scale includes 14 items (scored between 0-4) and total scores range from 0 (severe balance impairment) to 56 (optimal balance status).
Time Frame
Up to 7 weeks
Title
Changes in muscle tone
Description
The modified Ashworth scale for spasticity will be used. A scale used in the clinic to assess muscle spasticity, the modification adds a level that incorporates the angle at which resistance appears and monitors the speed of passive movement with a one-second count. This scale is easy to use and can assess all joints, has a high degree of reliability and reproducibility. The score is interpreted as follows: 0 No increase in tone 1 slight increase in tone giving a catch when slight increase in muscle tone, manifested by the limb was moved in flexion or extension. 1+ slight increase in muscle tone, manifested by a catch followed by minimal resistance throughout (ROM ) 2 more marked increase in tone but more marked increased in muscle tone through most limb easily flexed 3 considerable increase in tone, passive movement difficult 4 limb rigid in flexion or extension
Time Frame
Up to 7 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: People who have suffered a stroke with an evolution between 6 months and 6 years. Optimal cognitive capacity and mentally competent to participate in the study and complete the required questionnaires. People able of standing upright, including those who need technical aids. Exclusion Criteria: Present some of the contraindications for a treatment with NESA XSIGNAL®: pacemakers, internal bleeding, not to apply electrodes on skin in bad condition, with ulcerations or wounds, acute febrile processes, acute thrombophlebitis and/or phobia to electricity. Not having signed the informed consent form. Presenting any additional injury or pathology during the study. Not having the optimal cognitive capacities for understanding and participating in the study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Mariola Lledó Amat, MSc
Phone
+34 637 87 68 50
Email
mariola.lledo101@alu.ulpgc.es
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mariola Lledó Amat, MSc
Organizational Affiliation
University of Las Palmas de Gran Canaria
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mariola Lledó Amat
City
Las Palmas De Gran Canaria
State/Province
Las Palmas
ZIP/Postal Code
35016
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mariola Lledó Amat, MSc
Phone
+34 637 87 68 50
Email
mariola.lledo101@alu.ulpgc.es
First Name & Middle Initial & Last Name & Degree
Raquel Medina-Ramírez, PhD
First Name & Middle Initial & Last Name & Degree
Aníbal Báez-Suárez, PhD
First Name & Middle Initial & Last Name & Degree
Adolfo Sancho-Francés., PhD

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
32208842
Citation
Li L, Scott CA, Rothwell PM; Oxford Vascular Study. Trends in Stroke Incidence in High-Income Countries in the 21st Century: Population-Based Study and Systematic Review. Stroke. 2020 May;51(5):1372-1380. doi: 10.1161/STROKEAHA.119.028484. Epub 2020 Mar 25.
Results Reference
result
PubMed Identifier
21441153
Citation
McKevitt C, Fudge N, Redfern J, Sheldenkar A, Crichton S, Rudd AR, Forster A, Young J, Nazareth I, Silver LE, Rothwell PM, Wolfe CD. Self-reported long-term needs after stroke. Stroke. 2011 May;42(5):1398-403. doi: 10.1161/STROKEAHA.110.598839. Epub 2011 Mar 24.
Results Reference
result
PubMed Identifier
27451353
Citation
Crichton SL, Bray BD, McKevitt C, Rudd AG, Wolfe CD. Patient outcomes up to 15 years after stroke: survival, disability, quality of life, cognition and mental health. J Neurol Neurosurg Psychiatry. 2016 Oct;87(10):1091-8. doi: 10.1136/jnnp-2016-313361. Epub 2016 Jul 22.
Results Reference
result

Learn more about this trial

Non-invasive Neuromodulation NESA Application in the Rehabilitation of Stroke Sequelae

We'll reach out to this number within 24 hrs